"Antimanic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that are used to treat bipolar disorders or mania associated with other affective disorders.
| Descriptor ID |
D018692
|
| MeSH Number(s) |
D27.505.696.277.950.025 D27.505.954.427.210.950.025 D27.505.954.427.700.872.025
|
| Concept/Terms |
Antimanic Agents- Antimanic Agents
- Agents, Antimanic
- Antimanic Drugs
- Drugs, Antimanic
- Antimanics
Antimanic Effect- Antimanic Effect
- Effect, Antimanic
- Antimanic Effects
- Effects, Antimanic
|
Below are MeSH descriptors whose meaning is more general than "Antimanic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antimanic Agents".
This graph shows the total number of publications written about "Antimanic Agents" by people in this website by year, and whether "Antimanic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antimanic Agents" by people in Profiles.
-
Nichols TA, Drayton SJ, Borckardt J, Taber DJ. Lithium dosing equations: are they accurate? Ann Pharmacother. 2014 May; 48(5):596-600.
-
Brandt HM, Popish SJ, Lott RS. Effect of omega-3 fatty acids on valproate plasma protein binding. Ann Clin Psychiatry. 2010 Nov; 22(4):280-2.
-
Snarr BS, Phan SV, Garner A, VandenBerg AM, Barth KS. Symptomatic bradycardia with oral aripiprazole and oral ziprasidone. Ann Pharmacother. 2010 Apr; 44(4):760-3.
-
Busch AB, Huskamp HA, Neelon B, Manning T, Normand SL, McGuire TG. Longitudinal racial/ethnic disparities in antimanic medication use in bipolar-I disorder. Med Care. 2009 Dec; 47(12):1217-28.
-
Moore GJ, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Uhde TW, Drevets WC, Manji HK. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry. 2009 Apr 21; 70(5):699-705.
-
Goldberg JF, Brooks JO, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, Miklowitz DJ, Ketter TA, Sachs GS, Thase ME. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry. 2009 Feb; 70(2):155-62.
-
Post RM, Ketter TA, Uhde T, Ballenger JC. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs. 2007; 21(1):47-71.
-
Feeny NC, Danielson CK, Schwartz L, Youngstrom EA, Findling RL. Cognitive-behavioral therapy for bipolar disorders in adolescents: a pilot study. Bipolar Disord. 2006 Oct; 8(5 Pt 1):508-15.
-
Masters KJ, Melonas JM. Lamotrigine and informed consent. J Am Acad Child Adolesc Psychiatry. 2004 Feb; 43(2):130-1; author reply 131-2.
-
Myrick H, Brady KT. The use of divalproex in the treatment of addictive disorders. Psychopharmacol Bull. 2003; 37 Suppl 2:89-97.